Natural Nootropics Powder Ampakine CAS No. 22503-72-6 IDRA - 21 for
IDRA-21 is an AMPAkine and benzothiadiazine derivative. It is
currently being researched in regards to its effects in memory
improvement, cognitive enhancement, stimulation and reversing
cognitive deficits. IDRA-21 does not produce neurotoxicity under
normal conditions but may worsen neuronal damage following ischemia
after stroke or seizures. One interesting aspect of IDRA-21 is that
it seems to work better in younger, healthier subjects. This is in
contrast to most other nootropic substances.
Product Name: IDRA-21
Other Name: 7-chloro-3-methyl-3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide
CAS #: 15180-02-6
Purity: 99% min.
Molecular Formula: C8H9ClN2O2S
Molecular Weight: 232.69
Our IDRA-21 has a purity not less than 99%.
- Application Information
IDRA-21 is an ampakine drug and a benzothiadiazine derivative.
IDRA-21 is a chiral molecule, with (+)-IDRA-21 being the active
form. IDRA-21 shows nootropic effects in animal studies,
significantly improving learning and memory. It is around 10–30
times more potent than aniracetam in reversing cognitive deficits
induced by alprazolam or scopolamine, and produces sustained
effects lasting for up to 48 hours after a single dose. The
mechanism for this action is thought to be through promoting the
induction of long-term potentiation between synapses in the brain.
In comparison to the benzoylpiperidine derived ampakine drugs,
IDRA-21 was more potent than CX-516, but less potent than CX-546.
Newer benzothiadiazide derivatives with greatly increased potency
compared to IDRA-21 have been developed, but these have not been
researched to the same extent, with the benzoylpiperidine and
benzoylpyrrolidine CX-series of drugs being favoured for clinical
development, most likely due to more favourable toxicity profiles
at high doses.
- Reference List of Available Nootropics:
|CAS||Product Name||Other Name|